WaterStone Capital
1124 Kane Concourse, Bay Harbor Islands, Florida, 33154, United States
Overview
WaterStone Capital is a private investment fund manager with intellectual property as the core. It provides financing for Chinese and foreign enterprises with intellectual property content in the form of equity investment, and provides diversified support for enterprises through post-investment management, including cross-border capital operations, business docking, and resource integration. The firm is formed by a team from China and the United States. Its team members have worked in major Chinese and foreign institutions and have complementary advantages. Partners have extensive experience in international mergers and acquisitions, investment management, intellectual property rights, and independent entrepreneurship.
- Total investments
- 1
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- LumiThera
Led · Series B · Oct 2017
LumiThera is a Seattle-based commercial-stage medical device company developing the Valeda Light Delivery System, a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders including dry age-related macular degeneration (AMD) and diabetic retinopathy. The company has been granted CE Mark authorization for Valeda in the European Economic Area, but Valeda is not approved by the U.S. Food & Drug Administration. LumiThera is completing enrollment in two prospective, randomized, double-masked clinical trials: LIGHTSITE II in Europe and LIGHTSITE III in the U.S., and is planning additional trials for diabetic macular edema and AMD. It raised approximately $14M in a Series C financing. The company intends to use the proceeds to commercialize Valeda, complete LIGHTSITE III enrollment, and pursue U.S. regulatory clearance. Led by President and CEO Clark Tedford, Ph.D., LumiThera focuses on office-based PBM treatments delivered by eye care specialists. LumiThera is a Seattle-based clinical-stage medical device company developing non-invasive photobiomodulation (PBM) treatments for ocular disorders using light-emitting diodes. Its lead product is the LT-300, an ophthalmologist LED office-based instrument being developed to treat dry age-related macular degeneration (AMD). The company is conducting the LIGHTSITE I study, a prospective, randomized, double-masked clinical trial in 30 dry AMD subjects using the LT-300 light delivery system. LumiThera plans to use recently raised funds to further develop the LT-300, pursue regulatory clearances in select countries outside the USA including the CE mark in Europe, and expand clinical and commercial activities. The company completed a $5.5M Series B round led by WaterStone Capital with participation from RPR Venture. Clark Tedford, Ph.D., serves as President and CEO.
Team
No current team members are available.